Tom Carroux
Angel Investor
San Francisco, United States
Tom Carroux is a Series A investor in San Francisco focused on Medical and Health Care. Tom Carroux has successfully launched new technologies in the United States and throughout the Americas, Asia and Europe.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Tom Carroux invests in
Stages Tom Carroux invests in
Countries Tom Carroux invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (67%)
- Health Care 2 (67%)
- Biotechnology 1 (33%)
- Medical Device 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Healionics has applied its expertise in synthetic biomaterials to develop a novel vascular graft (artificial blood vessel) that, unlike existing grafts, remains open to blood flow long-term without need for costly interventions. Its first commercial application will be as a more reliable means of vascular access for dialysis patients, with asubsequent application to treat peripheral artery disease. We have great results in multiple controlled animal studies, a large patent portfolio, established production capacity, and are ready to begin human studies later this year in preparation for market launch.Near-Term Problem / Market Opportunity: Vascular Access for Dialysis Kidney failure patients need to have their blood filtered 3 times per week via dialysis. This removes waste from the blood, which would otherwise cause them to die. However, current methods for repeatedly accessing the bloodstream for dialysis are unreliable. This problem is a huge contributor to the $50 billion per year that the U.S. spends on dialysis patients (7% of Medicare’s entire budget!). A vascular graft is often implanted under the skin (connecting an artery to a vein) to create an access site with sufficient bloodflow for dialysis -- but existing grafts tend to occlude quickly, requiring repeated expensive interventions to keep them open.Solution: STARgraft Because our vascular graft remains open to blood flow much longer than existing grafts, it can potentially satisfy a severe unmet clinical need for ready-to-use, safe, long-term dialysis access, while substantially reducing costs, illness and death rate among dialysis patients.Product Pipeline We have additional products in development, including an implantable port which will allow needle-free dialysis. Eliminating the use of needles would further reduce cost and illness among dialysis patients, and allow them to perform dialysis in the convenience of their own home. In addition, our platform STAR biomaterial can improve the performance of a wide range of implantable devices via its remarkable ability to prevent both infection and scar tissue. We currently have two corporate-funded development contracts to explore STAR material’s use in multiple other device applications. | $5.5M / Series A / Nov 07, 2023 | ||
| Deep Blue is developing a novel hernia mesh to address the unacceptably high rate of hernia occurrence and recurrence. Millions of hernia surgeries are done globally with billions of dollars in clinical cost. Their surgeon-invented mesh with integral suture-like extensions is designed to eliminate a key point of failure for conventional meshfixation - the mesh, suture, tissue interface - and to provide superior anchor strength. In addition, Their Anchor Clip fixation device design enables faster, stronger, easier mesh implantation. Deep Blue products enhance hernia surgery with a potentially significant impact on the $1.1B global hernia device market. Due to its simple yet revolutionary design, the T-Line Mesh has the potential to reduce hernia occurrence and recurrence by preventing or reducing mesh fixation failure. | $7M / Series A / Jun 28, 2022 | ||
| Deep Blue is developing a novel hernia mesh to address the unacceptably high rate of hernia occurrence and recurrence. Millions of hernia surgeries are done globally with billions of dollars in clinical cost. Their surgeon-invented mesh with integral suture-like extensions is designed to eliminate a key point of failure for conventional meshfixation - the mesh, suture, tissue interface - and to provide superior anchor strength. In addition, Their Anchor Clip fixation device design enables faster, stronger, easier mesh implantation. Deep Blue products enhance hernia surgery with a potentially significant impact on the $1.1B global hernia device market. Due to its simple yet revolutionary design, the T-Line Mesh has the potential to reduce hernia occurrence and recurrence by preventing or reducing mesh fixation failure. | Series A / Dec 08, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Tom Carroux invest in?
Tom Carroux invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tom Carroux?
Public channels for Tom Carroux include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Tom Carroux last invest?
The most recent investment recorded for Tom Carroux closed in Nov 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
